David M. Vigushin

4.8k total citations · 2 hit papers
42 papers, 3.9k citations indexed

About

David M. Vigushin is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, David M. Vigushin has authored 42 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Genetics. Recurrent topics in David M. Vigushin's work include Histone Deacetylase Inhibitors Research (12 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (8 papers) and Epigenetics and DNA Methylation (6 papers). David M. Vigushin is often cited by papers focused on Histone Deacetylase Inhibitors Research (12 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (8 papers) and Epigenetics and DNA Methylation (6 papers). David M. Vigushin collaborates with scholars based in United Kingdom, United States and Australia. David M. Vigushin's co-authors include R. Charles Coombes, Philip N. Hawkins, Mark B. Pepys, Simak Ali, Eric O. Aboagye, Sami Shousha, Paul Pace, John P. Alao, Nicholas F. Totty and J. Justin Hsuan and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David M. Vigushin

42 papers receiving 3.8k citations

Hit Papers

Human lysozyme gene mutat... 1993 2026 2004 2015 1993 1993 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Human lysozyme gene mutations cause hereditary systemic amyloidosis
    1993 550 citations Mark B. Pepys, Philip N. Hawkins et al. profile →
  2. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.
    1993 489 citations David M. Vigushin, Mark B. Pepys et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David M. Vigushin United Kingdom 27 2.3k 806 516 496 412 42 3.9k
Masaaki Toda Japan 31 1.2k 0.5× 704 0.9× 452 0.9× 565 1.1× 288 0.7× 194 6.1k
Hitoshi Ohmori Japan 37 2.0k 0.9× 627 0.8× 225 0.4× 431 0.9× 604 1.5× 207 5.1k
Bernard Pau France 36 1.9k 0.8× 688 0.9× 299 0.6× 357 0.7× 457 1.1× 123 4.6k
Robert A. Orlando United States 38 1.7k 0.8× 353 0.4× 433 0.8× 711 1.4× 578 1.4× 80 4.1k
Shinichi Kawai Japan 42 1.1k 0.5× 914 1.1× 393 0.8× 328 0.7× 359 0.9× 181 6.4k
Don E. Griswold United States 40 2.4k 1.1× 1.2k 1.5× 315 0.6× 1.2k 2.4× 501 1.2× 120 6.4k
Brian L. Hood United States 38 2.7k 1.2× 577 0.7× 232 0.4× 228 0.5× 576 1.4× 105 4.4k
Akihiro Sekine Japan 31 1.5k 0.7× 568 0.7× 800 1.6× 325 0.7× 191 0.5× 103 4.4k
David S. Loose United States 30 1.3k 0.6× 349 0.4× 419 0.8× 221 0.4× 258 0.6× 70 2.8k
P. Rieber Germany 15 1.8k 0.8× 353 0.4× 220 0.4× 494 1.0× 718 1.7× 36 4.3k

Countries citing papers authored by David M. Vigushin

Since Specialization
Citations

This map shows the geographic impact of David M. Vigushin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Vigushin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Vigushin more than expected).

Fields of papers citing papers by David M. Vigushin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Vigushin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Vigushin. The network helps show where David M. Vigushin may publish in the future.

Co-authorship network of co-authors of David M. Vigushin

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Vigushin. A scholar is included among the top collaborators of David M. Vigushin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Vigushin. David M. Vigushin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kenny, Laura, R. Charles Coombes, David M. Vigushin, et al.. (2007). Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging. 34(9). 1339–1347. 208 indexed citations
2.
Marson, Charles M., Stéphane Sengmany, John P. Alao, et al.. (2006). Structure–activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorganic & Medicinal Chemistry Letters. 17(1). 136–141. 16 indexed citations
3.
Palmieri, Carlo, et al.. (2006). Serum 25-hydroxyvitamin D levels in early and advanced breast cancer: Table 1. Journal of Clinical Pathology. 59(12). 1334–1336. 78 indexed citations
4.
5.
Palmieri, Carlo, et al.. (2005). Serum 25 hydroxyvitamin D levels in early and advanced breast cancer. Journal of Clinical Oncology. 23(16_suppl). 630–630. 6 indexed citations
6.
7.
Palmieri, Carlo, David M. Vigushin, & T. J. Peters. (2004). Managing malignant disease in patients with porphyria. QJM. 97(3). 115–126. 11 indexed citations
8.
Marson, Charles M., et al.. (2004). Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorganic & Medicinal Chemistry Letters. 14(10). 2477–2481. 16 indexed citations
9.
Vigushin, David M. & R. Charles Coombes. (2004). Targeted Histone Deacetylase Inhibition for Cancer Therapy. Current Cancer Drug Targets. 4(2). 205–218. 76 indexed citations
10.
Varshochi, Rana, Andrew Sunters, John P. Alao, et al.. (2004). ICI182,780 Induces p21 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor α from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line. Journal of Biological Chemistry. 280(5). 3185–3196. 59 indexed citations
11.
Sanderson, Lisa, Graham W. Taylor, Eric O. Aboagye, et al.. (2004). PLASMA PHARMACOKINETICS AND METABOLISM OF THE HISTONE DEACETYLASE INHIBITOR TRICHOSTATIN A AFTER INTRAPERITONEAL ADMINISTRATION TO MICE. Drug Metabolism and Disposition. 32(10). 1132–1138. 74 indexed citations
12.
Vigushin, David M., Greg N. Brooke, Changgang Sun, et al.. (2004). Gliotoxin Is a Dual Inhibitor of Farnesyltransferase and Geranylgeranyltransferase I with Antitumor Activity Against Breast Cancer In Vivo. Medical Oncology. 21(1). 21–30. 87 indexed citations
13.
Marson, Charles M., et al.. (2002). Cyclic acid anhydrides as a new class of potent, selective and non-peptidic inhibitors of geranylgeranyl transferase. Bioorganic & Medicinal Chemistry Letters. 12(2). 255–259. 11 indexed citations
14.
Agarwal, Roshan, T. J. Peters, R. Charles Coombes, & David M. Vigushin. (2002). Tamoxifen-Related Porphyria Cutanea Tarda. Medical Oncology. 19(2). 121–124. 7 indexed citations
15.
Vigushin, David M. & R. Charles Coombes. (2002). Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs. 13(1). 1–13. 272 indexed citations
16.
Vigushin, David M., et al.. (2000). Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. European Journal of Cancer. 36(2). 177–182. 30 indexed citations
17.
Vigushin, David M., Grace K. Poon, Alan V. Boddy, et al.. (1998). Phase I and pharmacokinetic study of d -limonene in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 42(2). 111–117. 170 indexed citations
18.
Clesham, Gerald, David M. Vigushin, Philip N. Hawkins, et al.. (1997). Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance. The American Journal of Cardiology. 80(8). 1104–1108. 7 indexed citations
19.
Poon, Grace K., David M. Vigushin, Leslie J. Griggs, et al.. (1996). IDENTIFICATION AND CHARACTERIZATION OF LIMONENE METABOLITES IN PATIENTS WITH ADVANCED CANCER BY LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY. Drug Metabolism and Disposition. 24(5). 565–571. 39 indexed citations
20.
Booth, David R., Shouyong Tan, S E Booth, et al.. (1995). A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. QJM. 88(10). 695–702. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masaaki Toda Breakdown of academic impact, for papers by Hitoshi Ohmori Breakdown of academic impact, for papers by Bernard Pau Breakdown of academic impact, for papers by Robert A. Orlando Breakdown of academic impact, for papers by Shinichi Kawai Breakdown of academic impact, for papers by Don E. Griswold Breakdown of academic impact, for papers by Brian L. Hood Breakdown of academic impact, for papers by Akihiro Sekine Breakdown of academic impact, for papers by David S. Loose Breakdown of academic impact, for papers by P. Rieber
Rankless by CCL
2026